Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC et al (2012) Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013, 65:1–11. https://doi.org/10.1002/ART.37715

Geetha D, Jefferson JA (2020) ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis 75:124–137. https://doi.org/10.1053/j.ajkd.2019.04.031

Article  CAS  PubMed  Google Scholar 

Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, Kullman J, Lyons PA, Merkel PA, Savage COS et al (2020) ANCA-Associated Vasculitis. Nat Rev Dis Primers 6. https://doi.org/10.1038/S41572-020-0204-Y

Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, Dalhoff K, Dunogué B, Gross W, Holle J (2015) Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) consensus task force recommendations for evaluation and management. Eur J Intern Med 26:545–553. https://doi.org/10.1016/J.EJIM.2015.04.022

Article  PubMed  Google Scholar 

Monti S, Felicetti M, Delvino P, Padoan R, Berti A, Paolazzi G, Brunori G, Schiavon F, Caporali R, Montecucco C (2021) Anti-Neutrophil Cytoplasmic Antibody Specificity Determines a Different Clinical Subset in Granulomatosis with Polyangiitis. Clin Exp Rheumatol 39. https://doi.org/10.55563/clinexprheumatol/50919f

Alberici F, Jayne DRW (2014) Impact of rituximab trials on the treatment of ANCA-associated vasculitis. Nephrol Dial Transplant 29:1151–1159. https://doi.org/10.1093/NDT/GFT318

Article  CAS  PubMed  Google Scholar 

Treppo E, Binutti M, Agarinis R, De Vita S, Quartuccio L (2021) Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives. J Clin Med 10:3773. https://doi.org/10.3390/JCM10173773

Article  CAS  PubMed  PubMed Central  Google Scholar 

Delestre F, Charles P, Karras A, Pagnoux C, Néel A, Cohen P, Aumaître O, Faguer S, Gobert P, Maurier F et al (2023) Rituximab as Maintenance Therapy for ANCA-Associated Vasculitides: Pooled Analysis and Long-Term Outcome of 277 Patients Included in the MAINRITSAN Trials. Ann Rheum Dis 83:233–241. https://doi.org/10.1136/ARD-2023-224623

Article  Google Scholar 

Alba MA, Flores-Suárez LF (2016) Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why? Reumatol Clin 12:39–46. https://doi.org/10.1016/j.reuma.2015.06.002

Article  PubMed  Google Scholar 

Arnold J, Vital EM, Dass S, Aslam A, Rawstron AC, Savic S, Emery P, Md Yusof MY (2022) A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis. Front Immunol 12:803175. https://doi.org/10.3389/fimmu.2021.803175

Article  PubMed  PubMed Central  Google Scholar 

Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, Smith KGC, Jayne DRW (2015) Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 54:1153–1160. https://doi.org/10.1093/RHEUMATOLOGY/KEU452

Article  CAS  PubMed  Google Scholar 

Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, Holle JU, Hollinger N, Karadag O, Kronbichler A et al (2024) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 83:30–47. https://doi.org/10.1136/ARD-2022-223764

Article  PubMed  Google Scholar 

Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC et al (2021) 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res 73:1088–1105. https://doi.org/10.1002/acr.24634

Article  Google Scholar 

Floege J, Jayne DRW, Sanders JSF, Tesar V, Rovin BH (2024) Clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Kidney Int 105:S71–S116. https://doi.org/10.1016/j.kint.2023.10.008

Article  Google Scholar 

Chanouzas D, McGregor JAG, Nightingale P, Salama AD, Szpirt WM, Basu N, Morgan MD, Poulton CJ, Draibe JB, Krarup E et al (2019) Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study. BMC Nephrol. https://doi.org/10.1186/S12882-019-1226-0

Article  PubMed  PubMed Central  Google Scholar 

Gulati K, Edwards H, Prendecki M, Cairns TD, Condon M, Galliford J, Griffith M, Levy JB, Tam FWK, Tanna A et al (2021) Combination Treatment with Rituximab, Low-Dose Cyclophosphamide and Plasma Exchange for Severe Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Kidney Int 100:1316–1324. https://doi.org/10.1016/J.KINT.2021.08.025

Article  CAS  PubMed  Google Scholar 

Mcadoo SP, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J, Griffith M, Levy J, Cairns TD, Jayne D et al (2019) Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant 34:63–73. https://doi.org/10.1093/NDT/GFX378

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ysermans R, Busch MH, Aendekerk JP, Damoiseaux JGMC, van Paassen P (2023) Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: a retrospective study. J Transl Autoimmun 6:100178. https://doi.org/10.1016/J.JTAUTO.2022.100178

Article  CAS  PubMed  Google Scholar 

Cortazar FB, Muhsin SA, Pendergraft WF, Wallace ZS, Dunbar C, Laliberte K, Niles JL (2017) Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis. Kidney Int Rep 3:394–402. https://doi.org/10.1016/J.EKIR.2017.11.004

Article  PubMed  PubMed Central  Google Scholar 

Dirikgil E, Van Leeuwen JR, Bredewold OW, Ray A, Jonker JT, Soonawala D, Remmelts HHF, Van Dam B, Bos WJ, Van Kooten C et al (2022) ExploriNg DUrable Remission with Rituximab in ANCA-AssociatEd Vasculitis (ENDURRANCE Trial): protocol for a randomised controlled trial. BMJ Open. https://doi.org/10.1136/BMJOPEN-2022-061339

Article  PubMed  PubMed Central  Google Scholar 

Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage COS, Sinico RA, Stegeman CA (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180–2188. https://doi.org/10.1681/ASN.2007010090

Article  CAS  PubMed  Google Scholar 

Walsh M, Collister D, Zeng L, Merkel PA, Pusey CD, Guyatt G, Au Peh C, Szpirt W, Ito-Hara T, Jayne DRW (2022) The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ. https://doi.org/10.1136/bmj-2021-064604

Article  PubMed  Google Scholar 

Trivioli G, Vaglio A (2020) The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy. Clin Exp Immunol 202:403. https://doi.org/10.1111/CEI.13515

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R (2009) C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 20:289–298. https://doi.org/10.1681/ASN.2008050497

Article  CAS  PubMed  Google Scholar 

Merkel PA, George MD, Yue H, Popov T, Kronbichler A, Little MA, Jayne DRW (2025) Safety of Avacopan for the Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Combined Data From Three Clinical Trials. ACR Open Rheumatol 7. https://doi.org/10.1002/acr2.70001

Jayne DRW, Merkel PA, Schall TJ, Bekker P (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384:599–609. https://doi.org/10.1056/nejmoa2023386

Article  CAS  PubMed  Google Scholar 

Chalkia A, Flossmann O, Jones R, Nair JR, Simpson T, Smith R, Willcocks L, Jayne D (2024) Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage. Nephrol Dial Transplant 39:1473–1482. https://doi.org/10.1093/ndt/gfae020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortazar FB, Cerda J, Dhanani R, Roglieri J, Santoriello D (2023) Avacopan in patients with rapidly progressive glomerulonephritis requiring dialysis. Kidney Int Rep 8:1687–1691. https://doi.org/10.1016/j.ekir.2023.05.017

Article  PubMed  PubMed Central  Google Scholar 

Faurschou M, Westman K, Rasmussen N, De Groot K, Flossmann O, Höglund P, Jayne DRW (2012) Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3472–3477. https://doi.org/10.1002/ART.34547

Article  CAS  PubMed  Google Scholar 

Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, De Zoysa J, Espigol-Frigolé G et al (2019) Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis 78:399–405. https://doi.org/10.1136/ANNRHEUMDIS-2018-214245

Article  CAS